Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > 72% CR at any point in time.

<< Previous

Bullboard Posts

Next >>

Comment by CancerSlayeron May 01, 2023 2:12am

153 Views

Post# 35422221

RE:RE:RE:RE:72% CR at any point in time.

NotinKansas wrote: CS, I agree that removing the 12 undertreated would provide a clearer picture, and the overall results would indeed improve. But if you recalculate efficacy and duration without those 12, you also have to deduct the CRs and IRs they have yielded (and which now are included in the data presentation), otherwise you end up with too rosy numbers.

If my numbers are correct (will blame my age if they're not), dismissing the first 12 would yield a 23% improvement in our durable response. I can live with that...

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China